Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.76 |
|---|---|
| 52-week range | $3.43 - $43.07 |
| 50-day moving average | $6.70 |
| 200-day moving average | $14.00 |
| Wall St. target price | $22.20 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.76 from 2022-01-20
| 1 week (2022-01-13) | -0.79% |
|---|---|
| 1 month (2021-12-22) | -16.63% |
| 3 months (2021-10-22) | -71.05% |
| 6 months (2021-07-22) | -70.72% |
| 1 year (2021-01-18) | N/A |
|---|---|
| 2 years (2020-01-18) | N/A |
| 3 years (2019-01-18) | N/A |
| 5 years (2017-01-18) | N/A |
| Revenue TTM | $752,000 |
|---|---|
| Gross profit TTM | $-40,126,000 |
| Return on assets TTM | -26.13% |
| Return on equity TTM | -64.71% |
| Profit margin | 0% |
| Book value | $7.38 |
| Market capitalisation | $147.6 million |
TTM: trailing 12 months
We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.
Bolt Biotherapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.